LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting expression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.
1 . A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of lactic acid dehydrogenase A (LDHA) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region,
wherein the antisense strand comprises at least 19 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence 5′-AUCAGAUAAAAAGGACAACAUGC-3′ (SEQ ID NO:3408), wherein the antisense strand is 19-23 nucleotides in length,
wherein all of the nucleotides of the sense strand are modified nucleotides,
wherein the sense strand contains at least one motif of three 2′-F modifications on three consecutive nucleotides at or near the cleavage site,
wherein all of the nucleotides of the antisense strand are modified nucleotides,
wherein the antisense strand contains at least one motif of three 2′-O-methyl modifications on three consecutive nucleotides at or near the cleavage site, and
wherein a ligand comprising one or more N-acetylgalactosamine (GalNAc) derivatives attached through a monovalent, bivalent, or trivalent branched linker is conjugated to at least one strand of the agent.
2 . The dsRNA agent of claim 1 , wherein the antisense strand comprises at least 20 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence 5′-AUCAGAUAAAAAGGACAACAUGC-3′ (SEQ ID NO:3408).
3 . The dsRNA agent of claim 1 , wherein the antisense strand comprises at least 21 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence 5′-AUCAGAUAAAAAGGACAACAUGC-3′ (SEQ ID NO:3408).
4 . The dsRNA agent of claim 1 , wherein at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide, a 3′-terminal deoxy-thymine (dT) nucleotide, a 2′-O-methyl modified nucleotide, a 2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an unlocked nucleotide, a conformationally restricted nucleotide, a constrained ethyl nucleotide, an abasic nucleotide, a 2′-amino-modified nucleotide, a 2′-O-allyl-modified nucleotide, 2′-C-alkyl-modified nucleotide, 2′-hydroxly-modified nucleotide, a 2′-methoxyethyl modified nucleotide, a 2′-O-alkyl-modified nucleotide, a morpholino nucleotide, a phosphoramidate, a non-natural base comprising nucleotide, a tetrahydropyran modified nucleotide, a 1,5-anhydrohexitol modified nucleotide, a cyclohexenyl modified nucleotide, a nucleotide comprising a phosphorothioate group, a nucleotide comprising a methylphosphonate group, a nucleotide comprising a 5′-phosphate, a nucleotide comprising a 5′-phosphate mimic, a glycol modifice nucleotide, and a 2-O—(N-methylacetamide) modified nucleotide, and combinations thereof.
5 . The dsRNA agent of claim 1 , wherein the modified nucleotides are selected from the group consisting of a 2′-O-methyl modified nucleotide and a 2′-fluoro modified nucleotide.
6 . The dsRNA agent of claim 1 , wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide.
7 . The dsRNA agent of claim 1 , wherein the agent further comprises at least one phosphorothioate or methylphosphonate internucleotide linkage.
8 . The dsRNA agent of claim 7 , wherein the sense strand comprises at least one phosphorothioate internucleotide linkage at the 5′ terminus.
9 . The dsRNA agent of claim 7 , wherein the antisense strand comprises at least one phosphorothioate internucleotide linkage at the 3′ terminus.
10 . The dsRNA agent of claim 7 , wherein the antisense strand comprises four phosphorothioate internucleotide linkages.
11 . The dsRNA agent of claim 1 , wherein the ligand is conjugated to the 3′ end of the sense strand of the dsRNA agent.
12 . The dsRNA agent of claim 1 , wherein the ligand comprises four GalNAc derivatives attached through a monovalent, bivalent, or trivalent branched linker.
13 . The dsRNA agent of claim 12 , wherein the monovalent, bivalent, or trivalent branched linker comprise an oxygen atom and/or a substituted or unsubstituted alkylene wherein one or more methylene groups can be interrupted or terminated by O, NH, C(O), C(O)NH, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocyclyl.
14 . The dsRNA agent of claim 13 , wherein the monovalent, bivalent, or trivalent branched linker comprise a substituted or unsubstituted alkylene wherein one or more methylene groups can be interrupted or terminated by O, NH, C(O), or C(O)NH.
15 . The dsRNA agent of claim 1 , wherein the first base pair of the double stranded region from the 5′ end of the antisense strand is an AU base pair.
16 . The dsRNA agent of claim 1 , wherein the double stranded region comprises 26 nucleotides.
17 . The dsRNA agent of claim 1 , wherein the double stranded region exhibits 100% complementarity between the sense and antisense strands.
18 . The dsRNA agent of claim 1 , wherein the dsRNA agent is in a salt form.
19 . The dsRNA agent of claim 1 , wherein the dsRNA agent is capable of knocking down LDHA expression by at least 70% in a cell when provided as a single dose at 10 nM to the cell.
20 . The dsRNA agent of claim 1 , wherein the dsRNA agent is capable of knocking down LDHA expression by at least 80% in a cell when provided as a single dose of 10 nM to the cell.
21 . The dsRNA agent of claim 1 , wherein the antisense strand is 22 nucleotides in length.
22 . A cell containing the dsRNA agent of claim 1 .
23 . A pharmaceutical composition for inhibiting expression of a lactic acid dehydrogenase A (LDHA) gene comprising the dsRNA agent of claim 1 .
24 . The pharmaceutical composition of claim 23 , wherein the dsRNA agent is formulated in an unbuffered solution.
25 . The pharmaceutical composition of claim 23 , wherein the dsRNA agent is formulated with a buffered solution